Rectal formulations ceftriaxoneWith other funding (Saving Lives at Birth and BMGF) we have developed several candidate rectal formulations of ceftriaxone which have undergone preclinical testing., Two formulations (hard-shell gelatin capsule and rectodispersible mannitol-based tablet) have been selected for clinical development. We manufactured clinical batches in this award however they were not tested since the products did not meet the specifications of the parenteral formulations. We are refining the manufacturing process to address this.Therapeutic Intervention - DrugInitial developmentUnder active development/distribution2023We will evaluate this product in healthy adults to assess bioavailability and tolerability. If the development continues ultimately it will lead to improved delivery of clinical service through timely access to antibiotics for infants in remote areasMos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue) is the Rare Disease clinical trial running funded by this grant (IRAS 303113, Ethics approval 22-WA-0326). We have recruited 10 patients in 2024.We are actively recruiting at King's and due to open other national and international sites.Diagnostic Tool - Non-ImagingInitial developmentUnder active development/distributiontrueNCT060536712025as aboveMos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue) is the Rare Disease clinical trial running funded by this grant (IRAS 303113, Ethics approval 22-WA-0326). We have recruited 3 patients. We have further 5 who have expressed interest and are awaiting a recruitment appointment and further 6 awaiting consent for contact. MENTOR is the trial to which I am Chief Investigator, which we are submitting for our mTOR node work which will fund extension of MosFED to the other UK Research sitThis trial is still running and diagnostic tools are not yet evaluated.Diagnostic Tool - Non-ImagingInitial developmentOn holdtrue2024naMos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue) is the Rare Disease clinical trial running funded by this grant (IRAS 303113, Ethics approval 22-WA-0326). We have now recruited 17 patients, recruiting has opened and is ongoing in Newcastle, Oxford and UCLH.We have nearly reached our UK recruitment target of 20 patients, having recruited 17 at King's. ONe patient was recruited by collaborators in Newcastle, with further 2 projected at each Oxford and Cambridge. UCLH has also opened for recruitment. We will also be testing FCD tissue donated for reasearch held under separate Brain Bank Ethics approval, whilst not recruiting them into MosFED directly. We hope to be collecting 10 further FCDII samples under Brain Bank Ethics approval and further 10 from our International collaborators by the end of June 2026 when recruitment will close. Analysis of data will continue as planned until 2028.Diagnostic Tool - Non-ImagingUnder active development/distribution2026We are hoping to develop non-invasive diagnostic tools for FCD, and use novel sequencing methods to detect genetic mutations causing FCDIIA/B.multiparametric liver magnetic resonance imagingMultiparametric liver MRI has been used by Perspectum Diagnostics for non-invasive liver assessment in adults. Our collaboration has led to the generation of data from young children, of which little imaging data is available, that the company can use to understand the relationship between liver imaging measures with non-imaging liver and metabolic health assessments and substantiate the use of their liver imaging method to identify children at risk of developing severe disease, in particular liver disease, which often presents when metabolic health is impaired.Diagnostic Tool - ImagingEarly clinical assessmentUnder active development/distribution2023The study findings show the feasibility and value of undertaking liver imaging in children populations.https://www.perspectum.com/our-company/news/livermultiscan-shown-to-be-a-cost-effective-alternative-to-liver-biopsies-for-monitoring-patients-with-autoimmune-hepatitisDefinitive RCTThe award was given to us to run a Feasibility Randomised Controlled Trial. Based on its initial findings, we received follow-on funds from the ESRC (as part of the Evaluation Development Fund award (EDF) scheme), in order to run a full (definitive) Randomised Controlled Trial. This Randomised Controlled Trial is now running.Products with applications outside of medicineEarly clinical assessmentActively seeking supporttrueISRCTN123665762025I cannot yet describe any such impacts before the testing of the intervention is complete.NHS service testing for ciliopathiesFirst use of clinical whole exome sequencing by the Yorkshire Regional Genetics Service for the diagnosis of ciliopathies (primary ciliary dyskinesia, Meckel-Gruber syndrome, Joubert syndrome). New services based on clinical whole exome sequencing has enabled testing of about 40-60 patients per annum for both the UK and for international referrals.Diagnostic Tool - Non-ImagingWide-scale adoptionUnder active development/distribution2013Improved diagnosis, prognosis and genetic counselling for ciliopathy patients and their familieshttp://www.leedsth.nhs.uk/a-z-of-services/molecular-genetics/test-pages/meckel-and-joubert-syndromes/NilNilProducts with applications outside of medicineInitial developmentOn hold2014NilGenomic tools for measuring DNA damageUsing Chip-chip/Chip-Seq methods to detect DNA damage [and repair] throughout genomes. Is being applied to genotoxicity testing and patient stratification of chemo drugs. Funded by: KTP [TSB/Agilent Technologies] NISCHR Cancer Genetics BRU CRUK Centre Clinical PHD fellow BBSRC/GSK Case awardSupport Tool - For Medical InterventionInitial developmentUnder active development/distribution2012Still being developed for different applications. Genotoxicity testing/stratified medicineOptimisation of resting state fMRI and memory fMRIRefinement of resting state fMRI using hyperband imaging. I am currently testing the utility of this to lateralise language functions in people with epilepsy. In people who are less likely to be able to perform a language task, this is likely to be more efficient reducing the recall rate of language tasks and reduced time in scanner. I am also using this to look at longitudinal connectivity changes after epilepsy surgery and laser interstitial thermotherapy.Diagnostic Tool - ImagingRefinement. ClinicalUnder active development/distribution2025Using re-fMRI we have described changes in the connectivity network of people with epilepsy compared to people with functional seizures. This work is ongoing and highlights the potential use of rsfMRI as an adjunct for the diagnosis of functional seizures.Diagnostic wound dressingLaboratory observational Ex-Vivo study to investigate the sensitivity and specificity of a smart dressing to detect clinically relevant wound infection Burn wound infections are difficult to diagnose, but may become serious if they are not treated quickly. To diagnose an infection, dressings need to be removed from the wound, which may slow the healing process. A new dressing Smartwound™ may help to diagnose wound infection without needing to remove the dressing. The Smartwound™ dressing changes colour in the presence of the infection-causing bacteria. Laboratory studies show that the dressing does change colour in the presence of bacteria, but before it can be used in patients, it needs to be tested with the bacteria found in human wounds. The new Smartwound™ dressing will not be tested on patients in this study. Samples of burn wound fluid, called exudate, which can be taken from wound swabs and used wound dressings when the patients have their dressings removed will be used. Exudate will be gathered from patients with and without wound infection to see whether the dressing changes colour in the presence of the bacteria that cause a wound infection. Dressing changes and swabs are part of the normal care routine for patients with burns. This study aims to test whether the Smartwound™ technology developed to detect infection in a dressing for burn wounds is effective in identifying infection.Diagnostic Tool - Non-ImagingRefinement. ClinicalUnder active development/distributiontrue2016This trial will give key supportive data about the sensitivity and specificity of our diagnostic wound dressing, which will leverage next level of funding from industrial collaborators. Also as well as helping to inform a clinical definition of burn wound infection.http://www.isrctn.com/ISRCTN13825483Smartwound dressing Ex-vivo clinical studyWe have developed prototype hydrogel wound dressings which respond to the cytotoxins secreted by bacteria in wounds as the wound becomes critically colonised with pathogenic bacteria. The dressing (like the SPaCE sensor) responds to the four primary wound microbes: Staphylococcus aureus Pseudomonas aeruginosa Candida species Enterococcus faecalis Wound infection Following injury, bacteria start to colonise a wound within seconds. Most small wounds heal without infection, but some wounds become infected. The problem is there is no clinically accepted definition of wound infection. The change in bacterial density in a wound which is healing or infected. Note that the initial trajectory of the infected / non-infected wounds are the same. The divergence point is the Critical Colonisation Threshold (CCT). Detecting the CCT We believe the CCT is the earliest point in the wound healing / infection continuum at which wound infection can be detected. Our infection sensor contains phospholipid vesicles (left) dispersed in a gel matrix which are lysed by bacterial toxins secreted at the CCT. The vesicles contain a high concentration, non-toxic dye, carboxyfluorescein, which becomes fluorescent on dilution outside of the vesicle in the hydrogel matrix.Diagnostic Tool - Non-ImagingRefinement. Non-clinicalActively seeking supporttrue2018This dressing is under development, but arising from the lipid vesicle is a fast, low-cost wound infection sensor concept: the SPaCE sensor: The SPaCE NtP swab sensor kit is a cheap, fast method of assessing wound health. Wounds are swabbed as part of standard care, the swab placed in our patented vesicle gel, left for 30-60 minutes and colour change observed. Bright green colour means that virulence factors associated with SPaCE pathogens were detected. The sensing concept is the same as that used in the Smartwound dressing. A further development, in early stage is The rapid, low-cost test for GBS: We are developing a low cost, fast (10-30 min) test for neonatal GBS. The test, based on the vesicle technology used in our SPaCE wound infection sensor, has been modified to be responsive to the ß-Haemolysin secreted by GBS (Streptococcus agalactiae).https://smartwound.co.ukTHANDAV dance routineTHANDAV is a form of freestyle dancing with flavours of Indian classical/folk dance. The THANDAV routine is developed in association with a seasoned choreographer to ensure the ease and safety of the steps being performed. There is a 2-min high intensity [80% of max heart rate (HR) achievement] segment followed by a 30-sec low intensity (40-60% max HR) segment, and four such repetitions constitute a single 10-min routine. The songs selected are all popular Bollywood/Indian film songs/ album hits of the season. The steps are choreographed so as to be easily done and repetitive. Four songs are selected for a single 10 min routine. At present we have 3 different routines ready with us which have already been taught to the study participants.Preventative Intervention - Behavioural risk modificationUnder active development/distribution2020THANDAV (Taking HIIT ANd Dance to Adolescents for Victory over Non Communicable Diseases (NCDs)) intervention is an innovative and novel approach to improve and sustain physical activity in adolescent girls and women. We have conducted a series of targeted 'THANDAV Workshops' in colleges/conferences primarily in Chennai, Mumbai, Ahmedabad and New Delhi cities. A team of THANDAV trainers (2-3 individuals) conducted one-day workshops at these places. The workshop began with a brief talk (30 mins) on the need for such a fitness routine that focuses on young girls/women and this was followed by a THANDAV dance session to teach the THANDAV routine. We have approached many aided (government supported) and unaided (private) schools in Chennai with this idea and they are willing to incorporate THANDAV into their weekly fitness (Physical Training/PT) classes in school. We think that this will be one of the most encouraging outcomes of the project. We plan to organize once a month workshops in Chennai for women working in some Government offices such as Tamil Nadu Electricity Board (TNEB), Corporation Office (Ripon Building), Shastri Bhavan, Accounts General (AG) Office and Income Tax office as they are primarily doing sedentary (desk) jobs with no time for exercise. These women largely belong to the middle-income strata and typically face the socio-cultural barriers such as lack of time, no exclusive place for women to exercise, domestic duties, fear of going to parks or gyms etc. Our 'THANDAV' intervention 'fits the bill' for this target audience as it focuses on young girls and women with an aim to overcome these barriers and make a viable, feasible and sustainable physical activity intervention. At the National level, we approached the President of the Research Society for the Study of Diabetes in India (RSSDI) which is the largest association of diabetes experts (including doctors, nutritionists, educators, scientists etc.) in India and have received a letter of support from him as well in the month of December 2018. We plan to conduct THANDAV workshops at atleast 4-6 regional and/or national diabetes and NCD meetings across the country. Through these various workshops and on line community we will be able to disseminate THANDAV to atleast 25, 000 girls and women of all socio-economic strata.Clinical TrialApplication of Chronotherapy to Asthma: Towards the Personalisation of Asthma Management. A randomised, mechanistic study of 400μg Clenil® Modulite® (Beclometasone dipropionate) in the morning versus in the afternoon versus 200μg twice a day, in Patients with Atopic Mild to Moderate AsthmaTherapeutic Intervention - DrugEarly clinical assessmentUnder active development/distributiontrue2023Submission of manuscript to AJRCCM 2024Educational intervention vs usual care on anticoagulation therapy control based on a SAMe-TT2R2 score-guided strategyEducational intervention vs usual care on anticoagulation therapy control based on a SAMe-TT2R2 score-guided strategyManagement of Diseases and ConditionsRefinement. ClinicalUnder active development/distributiontrueTCTR201807110032013Used to help decision making about appropriateness of anticoagulation. Mentioned in 2020 ESC AF guidelinesMicrowave brain scannerWe are developing a portable, low-cost microwave brain scanner for detecting stroke inside ambulances or in rural areas. Part of the hardware is developed in China, the ODA country for this project, and it will be distributed by ET Medical, our ODA industrial partner. The scanner is in prototype stage, and it will be at preclinical stage by the end of the project. The main source of funding until July 2021 remains the DemoStroke project.Diagnostic Tool - ImagingRefinement. Non-clinicalUnder active development/distribution2021- New knowledge in algorithms and hardware. - Collaboration between the UK and China. - If successful, the device can revolutionise stroke diagnosis and therapy.Development of a novel TSPO PET marker for imaging neuroinflamationWe synthesised a novel PET marker for imaging neuroinflammation by TSPO that is not affected by the human genetic polymorphism to bindingDiagnostic Tool - ImagingInitial developmentOn hold2017From our pilot data we have obtained a MRC confidence in concept grant for further developmentDevelopment of Novel NMDA PET markerHuman studies have started in the application of this radiotracer in acute head injury patientsDiagnostic Tool - ImagingUnder active development/distribution2015N/ANovel PET tau probes V2Application for imaging tau pathology in dementiaDiagnostic Tool - ImagingInitial developmentUnder active development/distribution2015These radiotracers can also be used in transgenic mice models of dementia , therefor good for translation and small animal imaging of mice hence help 3R.New diagnostic and stratification method in IBDWe are currently developing a new IBD stratification strategy based on our new diagnostic tool and assay which will be classifying IBD patients according to a process driven pathological outcome. The diagnostic strategy will unify clinical diagnosis with biochemical and immunological response of IBD patients' leukocytes.Diagnostic Tool - Non-ImagingEarly clinical assessmentActively seeking support2020The diagnostic strategy which will unify already available clinical diagnostics with biochemical and immunological marker-based assays to stratify IBD patients for improved diagnosis, and patient selection to avoid unnecessary drug-exposures, economically benefit health-care to target and choose responsive patients.